The 12‐month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro‐oesophageal reflux disease

• Published in: Alimentary pharmacology & therapeutics 2011-02, Vol.33 (3), p.366-377
• Main Authors: Dabholkar, A. H., Han, C., Paris, M. M., Perez, M. C., Atkinson, S. N., Peura, D. A.
• Format: Article
• Language: English
• Subjects: 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects; Adolescent; Adult; Aged; Biological and medical sciences; Delayed-Action Preparations - administration & dosage; Dexlansoprazole; Digestive system; Dose-Response Relationship, Drug; Esophagus; Female; Gastroenterology. Liver. Pancreas. Abdomen; Gastroesophageal Reflux - drug therapy; Humans; Lansoprazole; Male; Medical sciences; Middle Aged; Other diseases. Semiology; Pharmacology. Drug treatments; Proton Pump Inhibitors - adverse effects; Statistics as Topic; Time Factors; Treatment Outcome; Young Adult
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1111/j.1365-2036.2010.04519.x

Aliment Pharmacol Ther 2011; 33: 366–377 Summary Background  Dexlansoprazole MR is a Dual Delayed Release formulation of dexlansoprazole, an enantiomer of lansoprazole, designed to extend the duration of acid suppression. Aim  To assess the 12‐month safety of dexlansoprazole MR in patients with symptomatic gastro‐oesophageal reflux disease (GERD). Methods  In this randomised open‐label study, patients received dexlansoprazole MR 60 or 90 mg once‐daily for 12 months. Safety was evaluated at months 1, 3, 6, 9 and 12/final visit through physical examinations, laboratory evaluations, endoscopies, gastric biopsies, fasting serum gastrin values and adverse events (AEs). Results  Of 591 patients receiving dexlansoprazole MR 60 and 90 mg, 71% and 65%, respectively, experienced ≥1 treatment‐emergent AE; the most frequent AE was upper respiratory infection (14% and 13% in the 60‐ and 90‐mg groups). Thirty patients experienced ≥1 serious AE; a majority of serious AEs were unrelated to study drug. No clinically meaningful change in any clinical laboratory parameters was noted. As expected, serum gastrin values rose with dexlansoprazole therapy; increases were not dose related. No clinically concerning trends were identified in gastric pathology results; no endocrine cell hyperplasia, adenocarcinoma, or lymphoma were observed. Conclusions  Twelve‐month treatment with dexlansoprazole MR 60 and 90 mg was well tolerated by GERD patients in this study (Clinicaltrials.gov identifier NCT00255190).